Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02239172 · ClinicalTrials.gov registry record · Phase 1
PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine
A Phase 1 study of Anthrax, sponsored by Fraunhofer, Center for Molecular Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02239172: Completed Phase 1 study of Anthrax, sponsored by Fraunhofer, Center for Molecular Biotechnology.
NCT02239172 is a Phase 1 study of Anthrax that has completed, run by Fraunhofer, Center for Molecular Biotechnology. The registered enrollment target is 30 participants, below the 773-participant average among 6 other Anthrax trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02239172, a Phase 1 study of Anthrax, has completed, sponsored by Fraunhofer, Center for Molecular Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purposes of this study is to evaluate and compare the safety, reactogenicity, and tolerability of the PA83-FhCMB vaccine candidate delivered at 4 dose levels with Alhydrogel
Conditions Studied
Interventions
- BIOLOGICAL PA83-FhCMB
Study Locations (1)
Maryland
- Walter Reed Army Institute of Research, Clinical Trials Center - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
What the finished NCT02239172 record still lists
NCT02239172 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 773-participant average among 6 other Anthrax trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Anthrax appearing as the primary indexed condition, and to 1 intervention - of which PA83-FhCMB is the first listed.
NCT02239172 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02239172 about?
NCT02239172 is a clinical study titled "PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine". The purposes of this study is to evaluate and compare the safety, reactogenicity, and tolerability of the PA83-FhCMB vaccine candidate delivered at 4 dose levels with Alhydrogel
What is the current status of trial NCT02239172?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2014-08. Estimated completion is 2015-05.
What conditions does trial NCT02239172 study?
This clinical trial studies the following conditions: Anthrax.
What interventions are being tested in trial NCT02239172?
The interventions under investigation include: PA83-FhCMB (BIOLOGICAL).
Who is sponsoring clinical trial NCT02239172?
This trial is sponsored by Fraunhofer, Center for Molecular Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02239172 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anthrax
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anthrax Vaccine Clinical Trials
COMPLETED · Phase 1
-
Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
RECRUITING
-
Anthrax AV7909 Boost Evaluation Study
ACTIVE NOT RECRUITING · Phase 2
-
VELOCITY: An Anthrax Vaccine Clinical Study
COMPLETED · Phase 3
-
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
COMPLETED · Phase 2
-
Febrile Whole Blood Specimen Collection and Testing
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia